In an open-label study, famotidine was added to the regular neurolepti
c regimen of 11 schizophrenic patients for 4 weeks. Each patient was s
cored weekly with SAPS, SANS, CGI and HAM-D-17 scales. The results sug
gest that famotidine is indeed effective as an adjunctive drug to neur
oleptics in the treatment of schizophrenia.